New mutated human papillomavirus-16 E7 polypeptide having a deleted sequence from amino acid 21 to 26, useful for manufacturing a medicament in the treatment or prevention of cancer, preferably cancer induced by a human papillomavirus

摘要

A mutated human papillomavirus-16 (HPV-16) E7 polypeptide (I) comprises a deleted sequence starting from amino acid 21 and encoding by amino acid 26 of the native wild type HPV-16 E7 complete polypeptide sequence. Independent claims are also included for the following: (1) a fusion protein comprising (I) linked to a tat polypeptide, preferably a human immunodeficiency virus-1 (HIV-1) tat peptide; (2) a polynucleotide encoding (I) or the fusion protein of (1); (3) a vector comprising (I), the fusion protein of (1) or the polypeptide of (2); (4) a cell transfected by or comprising the vector of (3); (5) an inhibitor directed against (I), the fusion protein of (1) or the polypeptide of (2); (6) a hybridoma cell expressing and producing the inhibitor of (5) or its active hypervariable portion; (7) a pharmaceutical composition comprising a carrier or diluent and (I), the fusion protein of (1), the polypeptide of (2), the vector of (3), the cell of (4) and/or the inhibitor of (5); (8) treatment or prevention of cancer affecting or supposed to affect a mammal, especially cancer induced by a human papillomavirus or HIV-16, comprising administering to the mammal the pharmaceutical composition of (7) in order to prevent or cure the symptoms of cancer or stop the development of tumors, in particular tumors induced by a human papillomavirus or HPV-16; and (9) obtaining a recombinant HPV E7 polypeptide from a yeast cell, comprising transforming a yeast cell culture, preferably a Pichia pastoris yeast cell culture with the vector of (3), selecting the cells transformed by the vector, culturing the selected transformed cells in an adequate culture medium, and obtaining and possibly purifying a recombinant HPV-16 E7 protein from the supernatant of the culture medium of the cells.